Treatment of hepatitis C;Hepatite C: Le traitement

Medecine Therapeutique

Volumn 5, Issue 7, 1999, Pages 531-536

  Poynard, Thierry ^a   Moussalli, Joseph ^a   Ratziu, Vlad ^a   Benhamou, Yves ^a   Regimbeau, Corrine ^a   Opolon, Pierre ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; RIBAVIRIN;

DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS C; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; PRACTICE GUIDELINE; REVIEW; TREATMENT OUTCOME;

EID: 0032746396     PISSN: 12646520     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Deuffic S., Buffat L., Poynard T., Valleron A.J. 1999. Modeling the hepatitis C virus epidemic in France. Hepatology 29 : 1596-1601.
2. Poynard T., Bedossa P., Opolon P. 1997. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349 : 825-832.
3. Shindo M., Di Bisceglie A.M., Hoofnagle J.H. 1992. Long-term follow-up of patients with chronic hepatitis C treated with alpha Interferon. Hepatology 15 : 1013-1016.
4. Marcellin P., et al. 1997. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon alpha therapy. Ann Intern Med 127 : 875-881.
5. Peters M. 1989. Mechanism of action of Interferons. Semin Liver Dis 9 : 235-239.
6. Mallat A., Preaux A.M., Blazejewski S., Rosenbaum J., Dhumeaux D., Mavier P. 1995. Interferon alpha and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 21 : 1003-1010.
7. Sing R.K., Gutman M., Bucana C.D., Sanchez R., Llansa N., Fidler I J. 1995. Interferon alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinoma. Proc Natl Acad Sci USA 92 : 4562-4566.
8. Hoofnagle J.H., et al. 1986. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha Interferon. N Engl J Med 315 : 1575-1578.
9. Poynard T., et al. 1996. Meta-analysis of Interferon randomized trials in the treatment of viral hepatitis C : effects of dose and duration. Hepatology 24 : 778-789.
10. Di Bisceglie A., et al. 1992. A pilot study of Ribavirin therapy for chronic hepatitis C. Hepatology 16 : 649-654.
11. Bodenheimer H.C., et al. 1997. Tolerance and efficacy of oral Ribavirin treatment of chronic hepatitis C : a multicenter trial. Hepatology 26 : 473-477.
12. Poynard T., et al. 1998. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352 : 1426-1432.
13. McHutchison J.G., et al. 1998. Interferon alpha 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339 : 1485-1492.
14. Davis G.L., et al. 1998. Interferon alpha 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339 : 1493-1499.
15. Poynard T., McHutchison J., Goodman Z., Albrecht J. 1999. Peut-on proposer un régime thérapeutique à la carte chez les patients atteints d'hépatite chronique C? Gastroenterol Clin Biol 23 : A153.
16. Schalm S.W., et al. 1997. Ribavirin enhances the efficacy but not the adverse effects of Interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 26 : 961-966.
17. Poynard T., et al. 1998. Impact of interferon alpha 2b and ribavirin on the liver fibrosis progression in patients with chronic hepatitis C. Hepatology 28 : 497 A.
18. Thevenot T., et al. 1997. Effects of cirrhosis, Interferon and Azathioprine on adverse events in patients with chronic hepatitis C treated with Ribavirin. J Viral Hepat 4 : 243-253.
19. Consensus Statement. 1999. EASL International Consensus Conference on Hepatitis C. J Hepatol 30 : 956-961.
20. Sobesky R., et al. 1999. Modeling the impact of IFN alpha treatment on liver fibrosis progression in chronic hepatitis C : a dynamic view. Gastroenterology 116 : 378-386.
21. Degos F., et al. 1998. Reinforced regimen of interferon alpha 2a reduces the incidence of cirrhosis in patients with chronic hepatitis C : a multicenter randomized trial. J Hepatol 29 : 224-232.
22. Nishiguchi S., et al. 1995. Randomized trial of effects of Interferon alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346 : 1051-1055.
23. Poynard T., et al. 1998. Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Société royale belge de Gastro-enterologie. Acta Gastroenterol Belg 61 : 431-437.
24. Poynard T. 1997. Should hepatitis C be treated ? What are indications of treatment in acute hepatitis C ? Gastroenterol Clin Biol 21 : S66-S69.
25. Camma C., Almasio P., Craxi A. 1996. Interferon as a treatment for acute hepatitis C. A meta-analysis. Dig Dis Sci 41 : 1248-1255.
26. Quin J.W. 1997. Interferon therapy for acute hepatitis C viral infection : a review by meta-analysis. Aust N Z J Med 27 : 611-617.
27. Lampertico P., et al. 1994. A multicenter randomized controlled trial of recombinant interferon alpha-2b in patients with acute transfusion-associated hepatitis C. Hepatology 19 : 19-22.
28. Viladomiu L., et al. 1992. Interferon-alpha in acute post transfusion hepatitis C : a randomized, controlled trial. Hepatology 15 : 767-769.
29. Hwang S.J., Lee S.D., Chan C.Y., Lu R.H., Lo K.J. 1994. A randomized controlled trial of recombinant interferon 2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol 21 : 861-866.
30. Li X.W., Zhu Z.V., Dao W.P., Liu F.H., Die G.S. 1993. Treatment of acute hepatitis C. Chung Hua Nei Ko Tsa Chih 32 : 409-411.
31. Omata M., et al. 1991. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 338 : 914-915.
32. Takano S., Satomura Y., Omata M., and Japan Acute Hepatitis Cooperative Study Group. 1994. Effect of interferon beta on Non-A, Non-B acute hepatitis : a prospective, randomized, controlled-dose study. Gastroenterology 107 : 805-811.
33. Calleri G., et al. 1998. Natural beta interferon in acute type-C hepatitis patients : a randomized controlled trial. Ital J Gastroenterol Hepatol 30 : 181-184.
34. Vogel W., et al. 1996. High-dose interferon-alpha 2b treatment prevents chronicity in acute hepatitis C : a pilot study. Dig Dis Sci 41 : 81S-85S.